ERLEADA (apalutamide): FOR ADULTS WITH PROSTATE CANCER WHO NEVER STOP SHOWING UP
Live Longer.
Lower PSA.

~7 out of 10 patients were alive on ERLEADA + ADT*†
*Vs 5.5 out of 10 on ADT alone.

~Twice as many men reached a zero PSA level‡
†Median follow-up was 44 months in patients with mCSPC.
‡65% of men on ERLEADA + ADT reached zero PSA (<0.2 ng/mL) vs 32% on placebo + ADT in patients
with mCSPC.
ADT=androgen deprivation therapy; mCSPC=metastatic castration-sensitive
prostate cancer;
PSA=prostate-specific
antigen.






